Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Clin Breast Cancer. 2021 May 24;22(1):32–42. doi: 10.1016/j.clbc.2021.05.009

TABLE 6:

CPS+EG Scores

Evaluable patients (N=66) ER and/or PR positive (N=36) TNBC (N=30)
CPS+EG score
   ≤ 2 20 (30%) 18 (50%) 2 (7%)
   ≥ 3 38 (58%) 17 (47%) 21 (70%)
   Indeterminate 8 (12%) 1 (3%) 7 (23%)
Responder = pCR and/or CPS+EG ≤ 2 31 (47%) 23 (64%) 8 (27%)
Non-responder = non-pCR or CPS+EG score ≥ 3 35 (53%) 13 (36%) 22 (73%)

Efficacy assessment by CPS+EG score. Responders included patients with pCR in the breast and/or CPS+EG score ≤ 2. Non-responders were patients with no pCR or CPS+EG score ≥ 3.